Percutaneous Coronary Intervention — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for percutaneous coronary intervention. 25 active patents protecting 4 drugs from 4+ originators. First major cliff: 2029. Daily refresh.

4
Approved drugs
25
Active US patents
62/100
Avg vulnerability
$1.3B
Annual revenue covered

Originators in Percutaneous Coronary Intervention

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 8 patents Novartis 8 patents Chiesi 7 patents Hikma Pharm Co Ltd 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating percutaneous coronary intervention. Each bar = one year. Y-axis scaled to peak year (5 patents).

2
27
2
28
3
29
5
30
1
33
4
35
4
36
4
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Brilinta
ticagrelor
 AstraZeneca 8 61 $1.1B 2030-04-17
Angiomax
BIVALIRUDIN
 Novartis 8 69 — 2028-07-27
Kengreal
CANGRELOR
 Chiesi 7 39 $200M 2029-05-13
Argatroban
ARGATROBAN
 Hikma Pharm Co Ltd 2 80 — 2027-09-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7589106 Argatroban method of use 80 2027-09-26
7687516 Argatroban method of use 80 2027-09-26
7582727 Angiomax other 75 2029-01-27
7598343 Angiomax other 75 2029-01-27
12472224 Angiomax method of use 75 2039-05-20
11903993 Angiomax method of use 75 2039-05-20
11918622 Angiomax method of use 75 2039-05-20
8425934 Brilinta other 68 2030-10-17
8425934 Brilinta other 68 2030-10-17
10300065 Brilinta method of use 62 2036-01-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9439921 Kengreal formulation 25 2035-07-10
9295687 Kengreal formulation 25 2035-07-10
9700575 Kengreal formulation 25 2035-07-10
10039780 Kengreal method of use 45 2035-07-10
8680052 Kengreal method of use 45 2033-03-09
8425934 Brilinta formulation 48 2030-04-17
9427448 Kengreal method of use 51 2030-11-10
8425934 Brilinta formulation 53 2030-04-17
11992514 Angiomax formulation 55 2039-05-20
9925265 Kengreal method of use 58 2029-05-13

Related